Ceritinib
- Generic Name
- Ceritinib
- Brand Names
- Zykadia
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36ClN5O3S
- CAS Number
- 1032900-25-6
- Unique Ingredient Identifier
- K418KG2GET
- Background
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-as...
- Indication
Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or...
- Associated Conditions
- Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.